Alkermes (ALKS) – Analysts’ Weekly Ratings Updates

Alkermes (NASDAQ: ALKS) recently received a number of ratings updates from brokerages and research firms:

• 7/30/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 7/29/2026 – Alkermes had its price target raised by JPMorgan Chase & Co. from $60.00 to $61.00. They now have a “neutral” rating on the stock.
• 7/29/2026 – Alkermes had its price target raised by Robert W. Baird from $48.00 to $58.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Alkermes had its “overweight” rating reaffirmed by Piper Sandler. They now have a $65.00 price target on the stock, up from $43.00.
• 7/20/2026 – Alkermes had its “buy” rating reaffirmed by Stifel Nicolaus. They now have a $63.00 price target on the stock, up from $45.00.
• 7/13/2026 – Alkermes had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Alkermes is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $60.00 price target on the stock.
• 7/2/2026 – Alkermes had its price target raised by Mizuho from $53.00 to $65.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Alkermes had its price target raised by Wells Fargo & Company from $44.00 to $65.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Alkermes had its “underperform” rating reaffirmed by Bank of America Corporation.
• 6/24/2026 – Alkermes had its price target raised by Needham & Company LLC from $54.00 to $61.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Alkermes had its price target raised by TD Cowen from $42.00 to $50.00. They now have a “buy” rating on the stock.
• 6/18/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 6/18/2026 – Alkermes had its price target raised by Needham & Company LLC from $50.00 to $54.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Alkermes had its price target raised by Royal Bank Of Canada from $45.00 to $56.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $51.51, for a total transaction of $463,590.00. Following the completion of the transaction, the executive vice president owned 73,389 shares of the company’s stock, valued at approximately $3,780,267.39. The trade was a 10.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Joseph Gaffin sold 2,034 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $54.03, for a total transaction of $109,897.02. Following the transaction, the executive vice president directly owned 227,490 shares of the company’s stock, valued at approximately $12,291,284.70. This trade represents a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 26,102 shares of company stock valued at $1,193,810. Insiders own 4.59% of the company’s stock.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.